Elvina Almuradova: HER2 Loss After Neoadjuvant Therapy in Breast Cancer – A New Prognostic Marker?
Elvina Almuradova, Ambassador at European School of Oncology, shared on LinkedIn about a recent paper by A. Papakonstantinou and T. Foukakis published in ESMO Annals of Oncology:
“HER2 Loss After Neoadjuvant Therapy in Breast Cancer: A New Prognostic Marker?
A recent systematic review and meta-analysis demonstrated that HER2 loss after neoadjuvant therapy is significantly associated with worse disease-free and overall survival compared to patients who retain HER2 positivity. These findings suggest that HER2 loss could serve as a potential prognostic factor in early-stage HER2-positive breast cancer.
Key Highlights:
HER2 loss is linked to a higher risk of recurrence and poorer overall prognosis.
Reassessment of HER2 status after neoadjuvant therapy might be critical for treatment planning.
The clinical benefit of continuing anti-HER2 therapy in patients with HER2 loss remains unclear.
But what does HER2 loss indicate—and why does it worsen prognosis?
Is this a true biological loss of HER2 expression, or rather the result of resistant HER2-negative clones persisting after therapy?
Do these patients no longer benefit from anti-HER2 treatment, or do they simply require a different post-neoadjuvant strategy?
These questions highlight the growing need for personalized approaches in breast cancer management.
What are your clinical experiences? Does HER2 loss after neoadjuvant therapy change your treatment strategy?”
Authors: A. Papakonstantinou and T. Foukakis
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023